List view / Grid view
24 April 2015 | By Victoria White
The combined spend on research and development (R&D) for the peer group of 35 mid-cap biotech companies increased by nearly $2 billion to reach a total of $9.7 billion in 2014, primarily thanks to top spenders Regeneron and Vertex, says leading research and consulting firm GlobalData.
16 April 2015 | By Victoria White
The melanoma treatment market will increase from $1.34 billion in 2013 to $5.64 billion by 2023, representing a robust CAGR of 15.5%, reports GlobalData...
15 April 2015 | By Victoria White
The global treatment market for Duchenne Muscular Dystrophy will expand in value at a CAGR of 160.5% to $990 million by 2019, says GlobalData...
7 April 2015 | By Victoria White
The combined total revenues for the peer group of 35 mid-cap biotech companies increased from $24.8 billion in 2013 to $26.5 billion in 2014, representing a Compound Annual Growth Rate (CAGR) of 21.9%, according to research and consulting firm GlobalData.
30 March 2015 | By Victoria White
BI and Lilly announce they have received a positive opinion from CHMP, recommending empagliflozin/metformin hydrochloride for the treatment type 2 diabetes...
26 March 2015 | By Victoria White
Germany pharmaceutical market value, valued at $58.6 billion in 2014, will grow modestly to reach an estimated $65 billion by 2020, says GlobalData...
26 March 2015 | By Victoria White
Following the first sepsis-specific product launch in 2016, the treatment market will expand to reach $354 million by 2021, says GlobalData...
20 March 2015 | By Victoria White
The global treatment market for Type 1 Diabetes (T1D) will expand from $6.6 billion in 2013 to an estimated $13.6 billion by 2023 according to GlobalData...
18 March 2015 | By Victoria White
The US pharmaceutical market is forecast to increase to $548.4 billion by 2020 according to research and consulting firm GlobalData...
11 March 2015 | By GlobalData
The steady decline in new Ebola cases presents a formidable challenge to current and future clinical trials of investigational treatments for the disease, as it will be more difficult to recruit study participants and demonstrate efficacy, says an analyst with research and consulting firm GlobalData...
6 March 2015 | By GlobalData
“AbbVie’s acquisition of Pharmacyclics (PCYC), valued at $21 billion, will help the company alleviate its dependency on Humira, which accounted for 62% of its total revenues in 2014, up from 57% in 2013..."
27 February 2015 | By GlobalData
Japan’s pharmaceutical market value is set to grow at a tepid Compound Annual Growth Rate (CAGR) of 1.3% from $72.8 billion in 2013 to reach $79.8 billion by 2020, driven by new product launches and the healthcare burden of the country’s aging population, according to research and consulting firm GlobalData...
26 February 2015 | By GlobalData
The global market for atrial fibrillation (AF) treatment will more than double in value from $4.6 billion in 2013 to peak sales of $9.4 billion in 2020, before declining to $5.7 billion by 2023 as new oral anticoagulants (NOACs) become genericized, according to research and consulting firm GlobalData...
18 February 2015 | By GlobalData
The Chinese treatment market for colorectal cancer will expand almost fourfold in value from an estimated $259 million in 2013 to $1.05 billion by 2023, at an impressive Compound Annual Growth Rate of 15.1%, according to research and consulting firm GlobalData...
17 February 2015 | By GlobalData
Insomnia drug sales will fall rapidly from $2.1 billion in 2013 to $1.4 billion by 2016, before steadily recovering to $1.8 billion by 2023, driven by the launch of two products, Merck & Co.’s Belsomra and Eisai’s E-2006, and an increase in the prevalent cases of insomnia, says research and…
